Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study suggests that combining bendamustine with tucidinostat may improve survival in patients with relapsed or refractory adult T-cell leukemia/lymphoma, highlighting its potential for clinical investigation.

This case report identifies a novel AR gene mutation in an adolescent with primary amenorrhea, suggesting that CAIS should be considered when evaluating patients with a female phenotype and breast development.

The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.

This review discusses rodent models of alopecia areata and suggests they are crucial for understanding the autoimmune mechanisms and potential treatments but reports no new clinical results.

In this study, the DIET-AI model, developed from a large dataset of over 200,000 images, demonstrated diagnostic performance for 31 skin diseases comparable to dermatologists of varying experience levels in 15 hospitals across China, supporting its potential effectiveness in clinical settings.

This study developed a testosterone-induced androgenetic alopecia model in BALB/c mice, finding that a 0.075 ml testosterone injection best replicated the dermal and hair follicle conditions of AGA patients, providing a promising tool for future drug testing and research into AGA therapies.

This study observed that GPT-4o, a generative AI model, showed high concordance with human providers in automating image-based SALT scores for assessing alopecia areata, suggesting its potential in assisting clinical evaluations without additional training.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study found that metabolic dysfunction-associated steatotic liver disease is linked to a higher risk of androgenetic alopecia, especially in women and individuals with certain lifestyle patterns.

This review discusses the development and potential therapeutic applications of adenosine receptor agonists and positive allosteric modulators, noting that while many clinical trials have been unsuccessful, initial results for new compounds are promising.

In this conference session, experts reviewed clinical evidence and strategies for using JAK inhibitors in managing alopecia areata, emphasizing optimal treatment practices and individual patient considerations to enhance safety and effectiveness in real-world settings.

This study describes an AI-powered system for diagnosing dermatological conditions, achieving a weighted score of 0.87 in both contextual understanding and diagnostic accuracy, suggesting it could enhance tele-dermatology applications by supporting remote consultations and care access in underserved regions.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study identified that certain genetic polymorphisms in IL-16 are associated with an increased risk of alopecia areata in an Iraqi population.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study developed a smart PVA-TPE/HA-AMP/SF/ALG wound dressing that shows promise in infected wound healing by providing bacterial resistance, promoting cell proliferation, and modulating inflammation through various signaling pathways, potentially reducing scar formation.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

This study evaluated azathioprine in treating alopecia areata and found that it was effective for 77.4% of patients, significantly reducing SALT scores after 6 months of treatment, with safety monitored through regular testing.

This study found that OR-101, a selective JAK3/TEK inhibitor, was associated with dose-dependent improvements in hair growth in humanized mice with alopecia areata, suggesting its potential as a treatment option.

This study found that the 3' UTR of JAM-A acts as a key competing endogenous RNA that supports dermal papilla cell function and hair follicle regeneration in alopecia areata.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

In this study, Rahim et al. found that keratinocyte differentiation requires changes in polyamine ratios mediated by AMD1, suggesting that targeting polyamine availability could be useful for treating hyperproliferative skin disorders.

This case report details a patient with myasthenia gravis and a malignant thymoma whose rising liver function tests, initially thought to be related to antibiotic use, were ultimately attributed to thymoma-associated multiorgan autoimmunity.

In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.

This study found that the free androgen index (FAI) is a superior marker of hyperandrogenism in men with premature androgenetic alopecia compared to DHEAS and testosterone levels.

This study analyzed social media posts on alopecia areata treatments and found that while most reported perceived improvement, many treatments, particularly dexamethasone, were associated with underlying negative emotions.

This study found that N‐AOHPA was particularly effective as a silicone emulsifier for improving the condition of damaged hair by preventing amino acid dissolution from bleached hair.